Medical experts found that patients who take certain antidepressants have a greater chance of gaining more weight than those ...

A study by Ethan Lazarus, MD, in presents a comprehensive review of the appropriate use of the fixed-dose, extended-release combination of naltrexone and bupropion (NB-ER) for the treatment of ...

For bupropion tablets, researchers only had data on costs from pharmacies and health care facilities, and the former had a higher price tag (median, $143.89 vs. $25.10).

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS ...

Bupropion XL: The typical starting dosage of bupropion XL for treating depression is 150 mg once per day. After 4 days, your doctor may increase your dosage to 300 mg per day (usually in the morning).

Bupropion is an antidepressant medication. Learn how bupropion interacts with alcohol, whether it is safe, and the potential side effects.

Bupropion Medication Information Learn everything you need to know about Bupropion-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it.

Auvelity contains bupropion and dextromethorphan, both of which are active ingredients in medicines with other uses. Talk to your health care provider before starting any new medicines or supplements.

Despite the severity of this issue, there is currently no FDA-approved medication specifically for treating MA use disorder. The ADAPT-2 trial publisehd results in Addiction and sought to address this ...

Bupropion inhibits noradrenaline and dopamine reuptake, whereas naltrexone is an opioid antagonist of the mesolimbic reward pathway, reducing rewards/pleasure-based or hedonic hunger.

Bupropion has been around for decades and was originally approved by the FDA in 1985 to treat depression. People who took bupropion reported greater energy and suppressed appetite, leading to the ...

DENVER -- Dextromethorphan-bupropion (known as AXS-05) delayed time to relapse in patients with Alzheimer's-related agitation, according to a phase III trial presented here. Compared with placebo ...